Clinical Trials
13 trialsNCT06778538 2025-01-16
HPGD-ccRCC
Lanzhou University Second Hospital
Completed
NCT00788125 2023-07-14
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
City of Hope Medical Center
Phase 1/2 Terminated
NCT01582009 2022-08-15
Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate
Roswell Park Cancer Institute
Phase 1/2 Terminated
NCT01253668 2021-04-13
Brivanib Metastatic Renal Cell Carcinoma
Abramson Cancer Center at Penn Medicine
Phase 2 Terminated
NCT01026337 2019-06-25
Magnetic Resonance Imaging (MRI) in Predicting Response to Sunitinib Malate in Patients With Locally Advanced or Metastatic Kidney Cancer
Abramson Cancer Center at Penn Medicine
Completed
NCT03692533 2018-10-02
Role of Geminin and Mcm-2 in Prognosis of Renal Cell Carcinoma
Assiut University
Phase NA Unknown
NCT00806650 2017-12-08
Anti-IMP3 Autoantibody and MicroRNA Signature Blood Tests in Finding Metastasis in Patients With Localized or Metastatic Kidney Cancer
City of Hope Medical Center
Completed
NCT00747305 2015-10-22
Sunitinib Before and After Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed By Surgery
Medical University of South Carolina
Phase 1 Terminated
NCT00908739 2015-09-30
Studying Tumor Tissue Samples From Patients Who Have Undergone Surgery for Localized Kidney Cancer
Case Comprehensive Cancer Center
Withdrawn
NCT00717587 2014-01-10
Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00900536 2013-08-12
DNA Analysis of Blood and/or Tissue Samples From Patients With Primary Kidney Cancer Receiving Sorafenib on Clinical Trial MRC-RE05-SORCE
National Cancer Institute (NCI)
Completed
NCT01158534 2012-08-07
Celecoxib and Recombinant Interferon Alfa-2b in Metastatic Kidney Cancer Who Have Undergone Surgery
Case Comprehensive Cancer Center
Phase 2 Completed
NCT00323791 2009-12-11
Gemcitabine With or Without Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer
Rutgers, The State University of New Jersey
Phase 2 Terminated